Ensemble Therapeutics Corporation Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today the extension of its strategic alliance with Bristol-Myers Squibb (NYSE: BMS), building on a collaboration initiated in April 2009.